SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The stock is currently experiencing high volatility and downward pressure as investors react to escalating geopolitical tensions in Iran and concerns over the administration's fiscal policies. Community discourse is sharply polarized, with active discussions focused on the potential economic impact of the ongoing conflict, questions surrounding the company's long-term financial viability, and the influence of current leadership on market stability.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense downward pressure, fueled by investor anxiety over Middle East geopolitical tensions and concerns about the asset's correlation with broader market sell-offs. While the community remains deeply polarized, discussions are dominated by debates over whether the current price action represents a structural failure of crypto as a 'safe haven' or an inevitable liquidity flush before a rebound.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is currently facing intense selling pressure as market participants weigh geopolitical instability in the Middle East and concerns over persistent inflation against recent federal policy moves. The community is heavily focused on the breakdown of key support levels, with many traders debating whether current market conditions warrant a defensive posture or present a rare entry point for long-term accumulation.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is facing intense downward pressure as geopolitical instability and rising oil prices fuel market-wide uncertainty. Investors are actively debating whether this decline represents a major correction or a buying opportunity, with sentiment heavily influenced by ongoing conflict and skepticism toward current geopolitical management.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently capturing significant investor attention following the launch of its Athena AI for general availability, which has fueled discussions around the company's long-term enterprise growth potential. While some community members remain frustrated by recent price volatility and broader market headwinds, many are actively debating the company's valuation against its improving fundamentals, including its path to GAAP profitability and increasing institutional interest.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing increased speculative interest and trading volume as community members debate the potential for pharmaceutical manufacturing contracts and broader corporate turnarounds. Traders are actively tracking job postings, recent patent activity, and regulatory pilot programs, viewing the stock as a low-float play capable of rapid momentum swings.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is seeing intense community debate following recent Q4 earnings and the filing of a proposal for potential reverse stock splits, which some investors fear signals further dilution. Meanwhile, shareholders are closely tracking Tonmya prescription data and market access wins as a catalyst for potential long-term growth and eventual profit.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is currently facing significant volatility as investors weigh the company's long-term pivot toward AI data center infrastructure against macro-level pressures and geopolitical uncertainty. While the community remains divided between those panic-selling amid broader market weakness and bulls accumulating shares based on the potential for imminent hyperscaler deal announcements, the stock continues to trade sideways as it awaits a clear catalyst to break its current consolidation range.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy Co. (GLND) is drawing intense investor focus following its recent business combination and Nasdaq debut, with community discussion centered on its potential to tap into vast oil reserves in the Jameson Land Basin. While some traders view the company as a high-upside speculative play backed by experienced leadership and strategic exploration rights, others express skepticism, frequently labeling it a volatile SPAC venture.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is generating significant market activity as investors weigh a potential strategic framework for U.S.-China manufacturing partnerships against ongoing challenges from vehicle recalls and EV market volatility. The stock is seeing heightened attention as traders monitor its recent 52-week highs and evaluate whether the companys pivot toward affordable hybrid and electric models can effectively navigate complex tariff environments and shifting consumer demand.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

Equity

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.


<ul class="summary-bullets"><li>Flat or more growth in Model Y/3 delivery numbers would demonstrate stability following the expiration of tax credit on the purchase of new electric vehicles in the U.S., he said.&nbsp;</li><li>Deepwater estimates that about 40% of Tesla’s overall sales come from the U.S., of which about three quarters took advantage of the now-expired tax credit.</li><li>Model S/X delivery numbers are ignorable, provided the vehicles are slated to end production in the second quarter, Munster said.</li></ul>Tesla Inc.’s (TSLA) Model Y and 3 deliveries will be the prime focus when the EV giant announces its first quarter delivery numbers next week, according to Deepwater Asset Management managing partner Gene Munster.Munster expects Tesla’s Model 3/Y delivery numbers will be at about 330,000 units, lower than Wall Street estimate of 351,000 units. “If Model 3 &amp; Y deliveries come in at 324k or better (vs. the Street at 351k), it is a win for TSLA shares,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://genemunster.com/tesla-delivery-preview-march-is-the-first-read-on-true-demand-focus-on-model-y-3/">said</a> in a statement, while adding that this would demonstrate stability following the expiration of tax credit on the purchase of new electric vehicles in the U.S.Deepwater estimates that about 40% of Tesla’s overall sales come from the U.S., of which about three quarters took advantage of the now-expired tax credit.<h2 class="st-heading-2">Overall Q1 Numbers</h2>The analyst now expects overall delivery volume in the three months through the end of March to come in at 345,000 units, marking a growth of 2%, but below a Wall Street estimate of about 366,000 units.While Tesla investors are now eyeing other developments at the company, including the development of its robotaxi network and improvement in the performance of its full self-driving driver assistance software, among others, “deliveries still matter,” Munster said.<h2 class="st-heading-2">Munster’s Delivery Estimates</h2>Model S/X delivery numbers are ignorable, provided the vehicles are slated to end production in the second quarter, Munster said. However, the vehicles will see a bump up in delivery numbers in the quarter on its way out, he noted.As for the company’s energy storage business, Munster expects Tesla’s energy deployments to be up 38% year-over-year in the quarter.“While shifting political landscapes and fluctuating federal subsidies create headwinds, there is a massive boom in battery storage (like Tesla’s Megapack and Powerwall business),” he noted.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TSLA stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> has gained 33% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 37% Following Reports Of A US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tesla electric vehicles are parked at a Tesla service center on August 2, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production

Gene Munster expects Tesla’s Model 3/Y delivery numbers will be at about 330,000 units, lower than Wall Street estimate of 351,000 units.

<ul class="summary-bullets"><li>The revisions were driven by Unity Vector, the company’s AI-powered ad platform, among other factors, the company said.</li><li>The company said it is discontinuing its ironSource Ads Network, effective April 30th.</li><li>The company also said it has engaged a financial advisor to assist with the divestiture of its Supersonic game publishing business.</li></ul>Shares of Unity Software Inc. (U) gained 14% after-hours on Thursday after the company raised its first-quarter(Q1) &nbsp;revenue guidance, bolstered by its artificial intelligence-powered ad platform Vector.The company also outlined plans, including divesting its game publishing business, to spur future revenue growth.<h2 class="st-heading-2">Fresh Guidance</h2>The San Francisco-based video game software development company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.unity.com/news/news-details/2026/Unity-Releases-Preliminary-First-Quarter-Results-Exceeding-Guidance-Will-Enhance-Growth-and-Profitability-by-Exiting-Non-Strategic-Ad-Businesses/default.aspx">expects</a> Q1 revenue of $505 million-$508 million, compared to its former estimate of $480 million-$490 million, and above an analyst estimate of $488.69 million, as per Fiscal AI. &nbsp;Adjusted core profit for the period is expected to be $130 million to $135 million, compared to former guidance of $105 million to $110 million, and above the $109.40 million expected by Wall Street.<h2 class="st-heading-2">What’s Driving The Performance?</h2>The revisions were driven by Unity Vector, the company’s AI-powered ad platform, among other factors, the company said."Unity Vector continues to deliver robust growth each quarter, driving results meaningfully above our guidance. Today’s actions will accelerate Vector’s impact on our business, enhancing both revenue growth and profitability,” said CEO Matt Bromberg.<h2 class="st-heading-2">Other Key Announcements</h2>The company also said it is discontinuing its ironSource Ads Network, effective April 30th. After the first quarter, the company expects minimal revenue contribution from the network.The company also said it has engaged a financial advisor to assist with the divestiture of its Supersonic game publishing business.These changes are expected to spur revenue growth, and increased adjusted core profit, the company noted. &nbsp;According to data from Koyfin, 18 of the 27 analysts covering Unity stock rate it ‘Buy’ or higher while nine rate it a ‘Hold’. The average 12-month price target on the stock is $32.33, representing a potential upside of about 89%.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around U stock improved from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/U">U stock</a> has fallen 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mdgl-stock-surges-most-in-month-on-eli-lilly-buyout-speculation/cZ3sam7RIlX">MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Unity Software, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 2, 2025. 

Unity Software Rallies By Over 14% After Hours On Fresh Q1 Revenue Guidance Above Street Expectations

The San Francisco-based video game software development company now expects Q1 revenue of $505 million to $508 million.

<ul class="summary-bullets"><li>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis.</li><li>The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis.</li><li>The company licensed global rights to six pre-clinical siRNA programs in February for up to $4.4 billion to expand its pipeline.</li></ul>Shares of Madrigal Pharmaceuticals Inc. (MDGL) closed 12% higher on Thursday on buyout speculation by pharma giant Eli Lilly and Company (LLY).The rumors originated after Madrigal featured on the Betaville <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.betaville.co.uk/betaville-intelligence/jrxmz7f0s1g9fqz992bo8ioi2lq6x3suvsc7">blog</a>, which highlights potential corporate transactions. The blog highlighted that the news is market gossip and added that it might be “total codswallop.”<h2 class="st-heading-2">Madrigal’s MASH Focus</h2>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious, progressive liver disease marked by fat accumulation, inflammation, and cell damage.The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis. The company is also evaluating the drug for the treatment of compensated MASH cirrhosis.<h2 class="st-heading-2">Madrigal’s Financials</h2>For full-year 2025, the company reported Rezdiffra net sales of $958.4 million. There were more than 36,250 patients on Rezdiffra as of the end of 2025, the company said.The company also licensed global rights to six pre-clinical siRNA programs from Suzhou Ribo Life Science Co. Ltd. &nbsp;and its subsidiary Ribocure Pharmaceuticals AB in February for up to $4.4 billion to expand its pipeline. The company is looking to undertake non-clinical studies for some of the candidates in 2026.In January, the company announced an exclusive global license agreement with Pfizer for Ervogastat in yet another attempt to expand its MASH pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MDGL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user opined that Lilly will be a great company to care for Madrigal while adding that the buyout must value the company between $800-$1000 per share.<stembedurl>https://www.stocktwits.com/sarkar20/message/648675460</stembedurl>Another proposed the idea of the company merging with Viking Therapeutics instead. Viking is developing a drug candidate called VK2809 for MASH as well.<stembedurl>https://www.stocktwits.com/vu_jade/message/648680850</stembedurl><a href="https://stocktwits.com/symbol/MDGL">MDGL stock</a> has gained 55% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-as-retail-traders-pile-into-obesity-pipeline-bets/cZ3sB3KRIlO">VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

<ul class="summary-bullets"><li>Hutt has been one of the key spokespeople for the company’s Trainium chips, the report noted.</li><li>The Information noted that Hutt is the second Annapurna leader to depart in the past seven months after Rami Sinno left to join Arm Holdings in August.</li><li>Other major exits at Amazon in recent times include the departure of Rohit Prasad, the company’s senior vice president and head scientist for artificial general intelligence (AGI), at the end of 2025.</li></ul>Amazon.com’s (AMZN) server-chip design unit Annapurna Labs’ leader Gadi Hutt has reportedly left the company.The Information <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.theinformation.com/briefings/amazon-ai-chip-product-leader-departs?rc=prcjzy">reported</a>, citing people familiar with the matter, that Hutt, a director of product and customer engineering, has left Amazon. The e-commerce giant acquired the Israeli chip startup Annapurna in 2015 for $350 million and Hutt has been one of the key spokespeople for the company’s Trainium chips, the report noted.Amazon Trainium is a family of custom-designed AI accelerators developed by Amazon Web Services (AWS) for high-performance training and inference of deep learning and generative AI models. The Trainium business has grown rapidly in recent months, driven largely by Anthropic’s extensive use of the chips to power its Claude AI models.<h2 class="st-heading-2">Other High Profile Exits At Amazon</h2>The Information noted that Hutt is the second Annapurna leader to depart in the past seven months after Rami Sinno left to join Arm Holdings in August. Sinno was director of engineering at Annapurna Labs.Other major exits at Amazon in recent times include the departure of Rohit Prasad, the company’s senior vice president and head scientist for artificial general intelligence (AGI), at the end of 2025 after leading its AGI organization and broader AI efforts. David Luan, head of Amazon’s AGI Lab, also left last month.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Shares of AMZN closed down 2% and edged up 0.2% after hours on Thursday. On Stocktwits, retail sentiment around AMZN stock stayed within the 'extremely bearish' territory while retail chatter stayed at normal' levels.<a href="https://stocktwits.com/symbol/AMZN">AMZN stock</a> has gained 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mdgl-stock-surges-most-in-month-on-eli-lilly-buyout-speculation/cZ3sam7RIlX">MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amazon logo displayed on a phone screen is seen in this illustration photo taken in Krakow, Poland.

Talent Exodus At Amazon? Annapurna Labs Leader Reportedly Departs Company

The Information reported, citing people familiar with the matter, that Gadi Hutt, a director of product and customer engineering at Annapurna, has left.

Business person Elon Musk delivers a speech during the World Economic Forum Annual Meeting in Davos, Switzerland, on January 22, 2026. (Photo by Harun Ozalp/Anadolu via Getty Images)

Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears

Musk on Thursday teased the possibility of Tesla launching a new three row SUV, in addition to its 7-seat Model Y.

<ul class="summary-bullets"><li>The divisions that suspended hiring reportedly have tens of thousands of employees, and managers have been instructed to halt the hiring of any new candidates who have not already been given a job offer, as per the report.&nbsp;</li><li>The company reportedly cited the need to restrain costs and improve margins for the decision.</li><li>The news comes on the heels of layoffs and hiring freezes across the tech industry in order to offset large investments in artificial intelligence.</li></ul>Windows OS maker Microsoft Corp. (MSFT) has reportedly paused hiring in major divisions including its Azure cloud. &nbsp;The Information <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.theinformation.com/articles/microsoft-freezes-hiring-major-cloud-sales-groups?rc=prcjzy">reported</a> on Thursday, citing employees familiar with the matter, that company executives told managers to suspend new hiring in its North American sales groups as well.“Azure Core no longer has room or approval to continue hiring,” Azure Core chief of staff Hilary Macfadden reportedly told Girish Bablani, President of Microsoft Azure Core, in an email earlier this month. Bablani leads the 11,000-person Azure engineering org.The divisions that suspended hiring reportedly have tens of thousands of employees, and managers have been instructed to halt the hiring of any new candidates not already given a job offer, as per the report.The company cited the need to restrain costs and improve margins for the decision, the report said, while also noting that it is routine for the company to slow hiring towards the end of its fiscal year in June.<h2 class="st-heading-2">Layoffs And Hiring Freezes Plague Tech Industry</h2>The news comes on the heels of layoffs and hiring freezes across the tech industry in a move aimed at offsetting large investments in artificial intelligence. Earlier this month, Reuters reported that Facebook parent Meta Platforms is planning sweeping layoffs that could affect 20% or more of the company as AI costs mount. Amazon also announced a major round of cuts impacting approximately 16,000 corporate roles globally in January.Microsoft’s hiring freeze is not companywide, and other departments, including the engineering division are still hiring, The Information reported, citing an employee. However, the company’s headcount has slowed in recent years after a surge in hiring from late 2021 to early 2022. It ended its last fiscal year with roughly 228,000 full time employees, about the same amount as a year earlier.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MSFT stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/MSFT">MSFT stock</a> has lost 6% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Microsoft Azure logo is seen displayed on a smartphone with a Microsoft logo in the background.

Microsoft Reportedly Pauses Fresh Hiring For Azure Cloud Segment Amid Broader Tech Layoffs Trend

The Information reported on Thursday, citing employees familiar with the matter, that company executives told managers to suspend new hiring in its North American sales groups as well.

<ul class="summary-bullets"><li>Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of its trial.</li><li>Jones Research attributed WVE’s selloff on Thursday to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%.</li><li>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat, while specifically preserving lean muscle mass.</li></ul> Shares of Arrowhead Pharmaceuticals Inc. (ARWR) fell nearly 2% on Thursday before paring back losses after Wave Life Sciences (WVE) announced mixed data from the early stage portion of its trial evaluating its investigational drug WVE-007 in individuals with obesity.Leerink analyst Mani Foroohar said that they are not surprised to see ARWR stock down as material obesity value is baked in at Arrowhead’s $8.5 billion market cap. The firm has a ‘Market Perform’ rating on Arrowhead shares.Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of the trial, with clinically meaningful reductions in visceral fat and waist circumference, after six months. The investigational drug was well tolerated to date up to 600 mg with no treatment discontinuations, the company said.<a href="https://stocktwits.com/symbol/WVE">WVE shares</a> traded 50% lower at the time of writing. &nbsp;<h2 class="st-heading-2">Why The WVE Selloff?</h2>Jones Research attributed WVE’s selloff to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%. The firm believes that while WVE-007 may not be competitive to GLP-1 category weight loss drugs in the general population, there is still a chance for utility in the elderly or patients with metabolic disease.Jones Research has a ‘Buy’ rating on Wave Life with a $35 price target.Leerink analyst Joseph Schwartz, meanwhile, said that the firm likes the continued improvement in visceral fat reduction at 240 mg after six months, as well as the larger reduction on waist circumference and measurable body weight reduction. The stock's reaction premarket seems to remove all value for WVE-007, which is "very overdone," the firm said. Leerink has an ‘Outperform’ rating on WVE shares.<h2 class="st-heading-2">Arrowhead’s Obesity Pipeline</h2>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat while specifically preserving lean muscle mass.While comparisons between Wave and Arrowhead data are impaired by small numbers of patients, differences in baseline, and other factors, the greater than 50% fall in Wave's stock price "highlights the degree of optimism baked into INHBE expectations" and brings questions related to Arrowhead "back to center stage," Foroohar told investors, as per TheFly.BofA, meanwhile, lowered the firm's price target on Arrowhead to $81 from $84 and kept a ‘Buy’ rating on the shares. The analyst said that Wave’s update appears largely priced in.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ARWR stock improved from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/htz-stock-soars-tsa-delays-airports-spike-in-car-rental-searches/cZ3sTFCRIke">HTZ Stock Soars After TSA Delays At Airports Reportedly Result In Spike In Car Rental Searches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?

Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.

<ul class="summary-bullets"><li>Shareholders reportedly alleged that Super Micro overstated its business prospects and ​inflated its stock price by knowingly failing to disclose that ⁠a significant portion of server sales went to companies in China.&nbsp;</li><li>The lawsuit is seeking unspecified damages for Super Micro investors between April 30, 2024, and March ​19, 2026, Reuters said.</li></ul>Super Micro Computers (SMCI) shareholders have reportedly sued the server maker alleging securities fraud, opening the latest chapter of the chip-smuggling controversy that wiped out billions from the company’s valuation on Friday.Last week, the U.S. charged three workers associated with Super Micro, including co-founder Yih-Shyan “Wally” Liaw, for their role in a scheme that enabled the smuggling of $2.5 billion worth of servers with Nvidia chips to China via Taiwan in violation of U.S. imposed chip export controls. A sales manager and a contractor were also charged and Liaw subsequently stepped down from the company’s board.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/super-micro-sued-by-shareholders-over-china-related-criminal-case-against-co-2026-03-25/">reported</a> on Wednesday that shareholders have filed a proposed class action in San Francisco federal ​court. They reportedly alleged that Super Micro overstated its business prospects and ​inflated its stock price by knowingly failing to disclose that ⁠a significant portion of server sales went to companies in China.The lawsuit is seeking unspecified damages for Super Micro investors between April 30, 2024, and March ​19, 2026, Reuters said. Shares of the company edged 0.5% lower in extended hours of trading at the time of writing.<h2 class="st-heading-2">SMCI’s Take On Indictment</h2>SMCI distanced itself from the controversy last week, saying that the company was not named as a defendant in the indictment.The company remains in full compliance with export rules and is cooperating fully with the government's investigation, it added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SMCI stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user recommended buying the bad news.<stembedurl>https://www.stocktwits.com/The_Swing_Trader/message/648578874</stembedurl><a href="https://stocktwits.com/symbol/SMCI">SMCI stock</a> has dropped 41% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srpt-stock-clocks-highest-daily-gain-in-nearly-8-years-after-rare-muscle-disorders-study-data/cZ3pTn6RIjd">SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A smartphone displays the logo of Super Micro Computer, Inc. (Photo illustration by Cheng Xin/Getty Images)

Super Micro Shareholders Press Company For Damages Over Chip-Smuggling Controversy

Reuters reported on Wednesday that shareholders have filed a proposed class action in San Francisco federal ​court.